Deinove has selected key markets of interest, identified strains from its library of bacteria, which indicate suitability for commercial deployment, and formed partnerships to expedite that process. While uncertainties remain, commercial revenues are expected in 2018 and development of revenues in line with our projections would indicate a potential valuation of €4.4/share.
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.